Copyright
©The Author(s) 2017.
World J Gastroenterol. Jul 28, 2017; 23(28): 5146-5157
Published online Jul 28, 2017. doi: 10.3748/wjg.v23.i28.5146
Published online Jul 28, 2017. doi: 10.3748/wjg.v23.i28.5146
Figure 7 Effects of monocyte-based therapy on chronically liver-damaged mice.
A: Hepatic levels of TGF-β1; B: Splenic levels of TGF-β1; C and D: Hepatic levels of IL-17 (C) and IL-23 (D). aP < 0.05; bP < 0.01. TGF-β: Transforming growth factor-beta; IL: Interleukin; BMMCs: Bone marrow mononuclear cells.
- Citation: de Souza VCA, Pereira TA, Teixeira VW, Carvalho H, de Castro MCAB, D’assunção CG, de Barros AF, Carvalho CL, de Lorena VMB, Costa VMA, Teixeira ÁAC, Figueiredo RCBQ, de Oliveira SA. Bone marrow-derived monocyte infusion improves hepatic fibrosis by decreasing osteopontin, TGF-β1, IL-13 and oxidative stress. World J Gastroenterol 2017; 23(28): 5146-5157
- URL: https://www.wjgnet.com/1007-9327/full/v23/i28/5146.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i28.5146